Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan; Genome and Systems Biology Degree Program, National Taiwan University, Taipei, Taiwan.
J Formos Med Assoc. 2019 Oct;118(10):1466-1470. doi: 10.1016/j.jfma.2019.07.003. Epub 2019 Jul 20.
Hodgkin lymphoma (HL) is a highly curable hematologic malignancy. Relapsed/refractory (R/R) HL is an important clinical challenge, despite advances in treatment. Brentuximab vedotin (BV) is highly effective in R/R HL in the western world. However, there are no real-world data on the use of BV in the Asian population. Our study aimed to evaluate the efficacy and safety of BV as salvage therapy in R/R HL patients in Taiwan. We recruited 20 R/R HL patients who received BV at National Taiwan University Hospital. BV was administered at 1.8 mg/kg once every 3 weeks. The median number of systemic treatment received before BV was three. The overall response rate was 73.7% with a complete remission rate of 21.1% in R/R HL. Overall survival was not reached and progression-free survival was 6.8 months. BV could strengthen disease control before transplantation and improve post-transplant outcomes, even among those heavily pretreated patients, without significant overlapping toxicities with prior therapies. Our data suggest that BV is well tolerated and effective in the treatment of Asian patients with R/R HL. BV may offer long-term disease control in selected patients.
霍奇金淋巴瘤（HL）是一种高度可治愈的血液恶性肿瘤。尽管治疗取得了进展，但复发/难治性（R/R）HL 仍然是一个重要的临床挑战。在西方国家，博纳吐单抗维布妥昔单抗（BV）在 R/R HL 中非常有效。然而，亚洲人群使用 BV 的真实世界数据尚缺乏。我们的研究旨在评估 BV 作为台湾 R/R HL 患者挽救性治疗的疗效和安全性。我们招募了在国立台湾大学医院接受 BV 治疗的 20 例 R/R HL 患者。BV 以 1.8mg/kg 的剂量每 3 周静脉输注一次。在接受 BV 治疗之前，患者接受的系统治疗中位数为 3 线。总体缓解率为 73.7%，完全缓解率为 21.1%。中位总生存期未达到，无进展生存期为 6.8 个月。BV 可以在移植前加强疾病控制，并改善移植后的结局，即使是那些接受过多线治疗的患者，与之前的治疗方案相比没有明显的重叠毒性。我们的数据表明，BV 在治疗亚洲 R/R HL 患者中具有良好的耐受性和有效性。BV 可能为部分患者提供长期疾病控制。
